RNAi therapeutics: an antiviral strategy for human infections

    Thumbnail
    Citations
    Altmetric
    Author
    Kelleher, AD; Cortez-Jugo, C; Cavalieri, F; Qu, Y; Glanville, AR; Caruso, F; Symonds, G; Ahlenstiel, CL
    Date
    2020-10
    Source Title
    Current Opinion in Pharmacology
    Publisher
    Elsevier BV
    University of Melbourne Author/s
    Caruso, Francesco; Cortez-Jugo, Christina; Cavalieri, Francesca; Qu, Yijiao
    Affiliation
    Collected Works
    Metadata
    Show full item record
    Document Type
    Journal Article
    Citations
    Kelleher, A. D., Cortez-Jugo, C., Cavalieri, F., Qu, Y., Glanville, A. R., Caruso, F., Symonds, G. & Ahlenstiel, C. L. (2020). RNAi therapeutics: an antiviral strategy for human infections. Current Opinion in Pharmacology, 54, pp.121-129. https://doi.org/10.1016/j.coph.2020.09.011.
    Access Status
    Access this item via the Open Access location
    URI
    http://hdl.handle.net/11343/251833
    DOI
    10.1016/j.coph.2020.09.011
    Open Access URL
    http://10.0.3.248/j.coph.2020.09.011
    Abstract
    Gene silencing induced by RNAi represents a promising antiviral development strategy. This review will summarise the current state of RNAi therapeutics for treating acute and chronic human virus infections. The gene silencing pathways exploited by RNAi therapeutics will be described and include both classic RNAi, inducing cytoplasmic mRNA degradation post-transcription and novel RNAi, mediating epigenetic modifications at the transcription level in the nucleus. Finally, the challenge of delivering gene modifications via RNAi will be discussed, along with the unique characteristics of respiratory versus systemic administration routes to highlight recent advances and future potential of RNAi antiviral treatment strategies.

    Export Reference in RIS Format     

    Collections